VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.
Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).
VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.
What if you could identify high risk patients at the earliest stage of their cardiovascular disease?
VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.
Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

The POC testing market is set to reach $40 billion by 2022.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

The POC testing market is set to reach $40 billion by 2022.

Mission

Our mission is to improve public health and the individual quality of life by developing unique, innovative concepts and products! 

We believe that early, accurate diagnosis is better than waiting for problems to arise.  A pro-active approach greatly benefits people’s health by identifying issues early in their development and preventing symptoms from occuring. This has a positive effect on performance, productivity and reputation.

Business strategy

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials for the food and pharmaceutical industry.
Vitak is also building long term select distribution channel partnerships worldwide to provide diverse innovative POC solutions needed in the healthcare sector. The company is continuously refining and expanding its global distribution partnerships.

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com